1stOncology™: Cancer Intelligence Service – Page 18335 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

10-K – Annual report [Section 13 and 15(d), not S-K Item 405]

Threshold Pharmaceuticals has filed a 10-K – Annual report [Section 13 and 15(d), not S-K Item 405] with the U.S. Securities and Exchange Commission (Filing, Threshold Pharmaceuticals, MAR 3, 2015, View Source [SID1234502166]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

10-K – Annual report [Section 13 and 15(d), not S-K Item 405]

Rigel has filed a 10-K – Annual report [Section 13 and 15(d), not S-K Item 405] with the U.S. Securities and Exchange Commission (Filing, Rigel, MAR 3, 2015, View Source [SID1234502165]).

10-K – Annual report [Section 13 and 15(d), not S-K Item 405]

MacroGenics has filed a 10-K – Annual report [Section 13 and 15(d), not S-K Item 405] with the U.S. Securities and Exchange Commission (Filing, MacroGenics, MAR 3, 2015, View Source [SID1234502164]).

François Legault is appointed Chairman of the Board of Verlyx Pharma, a biopharmaceutical company developing products targeting liver diseases.

On March 3, 2015 Verlyx Pharma Inc. reported the appointment of François Legault as Chairman of the Board, effective immediately (Press release, Verlyx Pharma, MAR 3, 2015, View Source [SID:1234513486]). Mr. Legault, a seasoned biotechnology and industrial technologies executive, joins Verlyx with more than 25 years of experience in the biotechnology sector.

"As we seek to move forward and establish the company as a frontrunner in the treatment of inflammatory liver diseases such as NASH (non-alcoholic steatohepatitis), we identified a remarkable leader who could bring vision, focus and a wealth of experience to maximize Verlyx’s potential," said Bernard Dorval, Acting Chairman of the Board. "The Board and shareholders are confident that François’ rich experience in the biotechnology sector, and in particular in the area of liver diseases, as well as his passion for leading high performing teams will help Verlyx establish itself as a leader in this field."

Mr. Legault was President, Chief Operating Officer and a cofounder of ViroChem Pharma Inc., a private biotechnology company which was acquired by Vertex Pharmaceuticals. Prior to that, he was a Senior Officer of BioChem Pharma Inc., another important biopharmaceutical company, from its inception until the company merged with Shire Pharmaceuticals Group plc.

"I am delighted to join Verlyx Pharma at a time when it is establishing its first-in-man clinical proof of concept with VLX103, focusing on the treatment of liver diseases," said François Legault, Verlyx’s new Chairman. "There are important unmet needs in this field which represent huge opportunities for the company’s portfolio of products. I am looking forward to working both with the Board and the management team led by Pierre Falardeau, President and Chief Executive Officer, as we advance our products toward commercialization."

Earlier today, Oncozyme Pharma had announced that it was changing its corporate name to Verlyx Pharma Inc. to reflect the corporation’s new focus on targeting inflammatory liver diseases. Verlyx Pharma, a privately held company, is dedicated to the discovery and development of drugs to treat liver disorders. The company’s lead product, VLX103, is a potent agent with hepatoprotective activity, specifically designed to target the liver and minimize non-targeted systemic exposure. Such properties give it an ideal profile for the treatment of liver diseases such as NASH and ASH (Free ASH Whitepaper) (alcoholic steatohepatitis). An increasing number of people are expected to be affected by liver diseases worldwide, and many analysts are calling NASH "the next big global epidemic".

Domain Therapeutics launches Specific Purpose Vehicle Kaldi Pharma to harness the potential of its adenosine programs

On March 3, 2015 Domain Therapeutics, a biopharmaceutical company specializing in the research and early development of new drug candidates targeting G protein-coupled receptors (GPCRs), reported the creation of a Specific Purpose Vehicle (SPV), Kaldi Pharma, for the exclusive development of its A2a/A1 and A2a antagonist programs (Press release, Domain Therapeutics, MAR 3, 2015, View Source;domain-therapeutics—kaldi-pharma-en.pdf [SID:1234508324]).

The mission of Kaldi Pharma is to exploit the patented series of A2a/A1 and A2a antagonists discovered by Domain Therapeutics in any indication in which inhibiting adenosine constitutes a valuable therapeutic approach.

Kaldi Pharma has granted a worldwide license to Clevexel Pharma for the development of the A2a/A1 preclinical candidate for Parkinson’s disease. CleveXel and Kaldi Pharma signed an agreement for sharing future revenues on the program.

Kaldi Pharma is expected to grant a second license for the A2a in oncology to another partner. It has recently been revealed that combining an A2a antagonist with immune checkpoint blockers results in enhanced antimetastatic effects.

After having entrusted the development of a first product to Prexton Therapeutics, with this SPV, Domain reaffirms its strategy to move forward the development of its products up to clinical proof-of-concept through dedicated entities enabling a flexible approach and an optimized value creation of its programs.

"For CleveXel, this partnership with Kaldi paves the way for real development of our company. We are very pleased with this license on the innovative molecule for Parkinson’s disease. CleveXel’s expertise in drug development will undoubtedly add value to this program," said Christian Bloy, President of CleveXel Pharma. "We will make this product a flagship project in our portfolio and take it through to clinical development."

"We are very excited by the creation of Kaldi and by the considerable potential of our novel generation of adenosine antagonists as drugs against Parkinson and cancer," said Pascal Neuville, CEO of Domain Therapeutics and president of Kaldi Pharma. "CleveXel is the perfect partner for Kaldi in CNS indications with their solid expertise in preclinical and clinical drug development."